Jongen Vita W, van Rooijen Martijn S, Schim van der Loeff Maarten F, Newsum Astrid M, de Vos Klootwijk Louise, Hoornenborg Elske, Hogewoning Arjan, van der Valk Marc, van den Berk Guido E L, Prins Maria, Heijman Titia
From the Department of Infectious Diseases, Public Health Service Amsterdam.
Amsterdam UMC, University of Amsterdam, Internal Medicine, Amsterdam Infection & Immunity Institute (AIII).
Sex Transm Dis. 2020 Sep;47(9):587-595. doi: 10.1097/OLQ.0000000000001223.
INTRODUCTION: As the incidence of hepatitis C virus (HCV) infections remains high among human immunodeficiency virus (HIV)-positive men who have sex with men (MSM) an HCV testing strategy was introduced at the sexually transmitted infections (STI) clinic in Amsterdam in 2017. We aimed to evaluate this HCV testing strategy. METHODS: The HIV-positive MSM and transgender women (TGW) were eligible for HCV testing (anti-HCV and HCV ribonucleic acid) at the STI clinic if they did not visit their HIV clinician in the 3 months before the consultation and had not been tested for HCV at the STI clinic in the previous 6 months. All eligible individuals were administered the 6 questions on risk behavior of the HCV-MSM observational study of acute infection with hepatitis C (MOSAIC) risk score; a risk score of 2 or greater made a person eligible for testing. RESULTS: From February 2017 through June 2018, 1015 HIV-positive MSM and TGW were eligible for HCV testing in 1295 consultations. Eleven active HCV infections (HCV ribonucleic acid positive) were newly diagnosed (positivity rate, 0.9%; 95% confidence interval [CI], 0.4-1.5%). Sensitivity and specificity of the HCV-MOSAIC score for newly diagnosed active HCV infections were 80.0% (95% CI, 49.0-94.3%) and 53.7% (95% CI, 50.8-56.5%), respectively. If an HCV-MOSAIC score of 2 or greater were used to determine whom to test, 46.6% of individuals currently tested for HCV would be eligible for testing. CONCLUSIONS: Using the new HCV testing strategy, HCV testing was done in 1295 consultations with HIV-positive MSM and TGW in 17 months. We newly diagnosed 11 active HCV infections. The HCV-MOSAIC risk score could reduce the number of tests needed, but some active HCV infections will be missed.
引言:由于丙型肝炎病毒(HCV)感染在与男性发生性关系的艾滋病毒(HIV)阳性男男性行为者(MSM)中发病率仍然很高,2017年阿姆斯特丹性传播感染(STI)诊所引入了一项HCV检测策略。我们旨在评估这项HCV检测策略。 方法:如果HIV阳性的男男性行为者和跨性别女性(TGW)在咨询前3个月内未就诊于其HIV临床医生,且在之前6个月内未在STI诊所进行过HCV检测,则有资格在STI诊所进行HCV检测(抗HCV和HCV核糖核酸检测)。所有符合条件的个体都接受了丙型肝炎急性感染男男性行为者观察性研究(MOSAIC)风险评分中关于风险行为的6个问题;风险评分为2或更高者有资格进行检测。 结果:从2017年2月到2018年6月,在1295次咨询中,1015名HIV阳性的男男性行为者和跨性别女性有资格进行HCV检测。新诊断出11例活动性HCV感染(HCV核糖核酸阳性)(阳性率为0.9%;95%置信区间[CI],0.4 - 1.5%)。新诊断的活动性HCV感染中,HCV - MOSAIC评分的敏感性和特异性分别为80.0%(95% CI,49.0 - 94.3%)和53.7%(95% CI,50.8 - 56.5%)。如果使用HCV - MOSAIC评分为2或更高来确定检测对象,目前接受HCV检测的个体中有46.6%将有资格进行检测。 结论:采用新的HCV检测策略,在17个月内对1295名HIV阳性的男男性行为者和跨性别女性进行了咨询检测。我们新诊断出11例活动性HCV感染。HCV - MOSAIC风险评分可以减少所需检测数量,但会遗漏一些活动性HCV感染。